vs
Side-by-side financial comparison of Anbio Biotechnology (NNNN) and QuidelOrtho Corp (QDEL). Click either name above to swap in a different company.
Anbio Biotechnology is a specialized in vitro diagnostic (IVD) biotechnology enterprise that develops, manufactures and markets a wide range of rapid testing solutions. Its product portfolio covers infectious disease detection, cardiovascular marker tests, food safety screening kits and supporting diagnostic tools, serving clinical labs, healthcare facilities and supervision bodies across global markets.
QuidelOrtho Corporation is an American manufacturer of diagnostic healthcare products that are sold worldwide.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q3 25 | — | $699.9M | ||
| Q2 25 | — | $613.9M | ||
| Q1 25 | — | $692.8M | ||
| Q4 24 | — | $707.8M | ||
| Q3 24 | — | $727.1M | ||
| Q2 24 | — | $637.0M | ||
| Q1 24 | — | $711.0M | ||
| Q4 23 | — | $742.6M |
| Q3 25 | — | $-733.0M | ||
| Q2 25 | — | $-255.4M | ||
| Q1 25 | — | $-12.7M | ||
| Q4 24 | — | $-178.4M | ||
| Q3 24 | — | $-19.9M | ||
| Q2 24 | — | $-147.7M | ||
| Q1 24 | — | $-1.7B | ||
| Q4 23 | — | $7.0M |
| Q3 25 | — | -100.7% | ||
| Q2 25 | — | -29.4% | ||
| Q1 25 | — | 4.7% | ||
| Q4 24 | — | -14.2% | ||
| Q3 24 | — | 2.1% | ||
| Q2 24 | — | -18.4% | ||
| Q1 24 | — | -247.3% | ||
| Q4 23 | — | 5.4% |
| Q3 25 | — | -104.7% | ||
| Q2 25 | — | -41.6% | ||
| Q1 25 | — | -1.8% | ||
| Q4 24 | — | -25.2% | ||
| Q3 24 | — | -2.7% | ||
| Q2 24 | — | -23.2% | ||
| Q1 24 | — | -239.9% | ||
| Q4 23 | — | 0.9% |
| Q3 25 | — | $-10.78 | ||
| Q2 25 | — | $-3.77 | ||
| Q1 25 | — | $-0.19 | ||
| Q4 24 | — | $-2.54 | ||
| Q3 24 | — | $-0.30 | ||
| Q2 24 | — | $-2.20 | ||
| Q1 24 | — | $-25.50 | ||
| Q4 23 | — | $0.11 |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
